Placeholder Banner

New USITC report shows "no credible evidence" supporting a TRIPs waiver expansion

October 17, 2023
Media Contact
JG
2027471281

The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning COVID-19 diagnostics and therapeutics.  

BIO’s Chief Policy Officer, John Murphy, made the following statement:  

“This report reiterates our stance that there is no credible evidence supporting the need for an expanded TRIPs waiver -- or other expansions that would hinder critical intellectual property protections within the biomedical field -- to increase global access to COVID-19 diagnostics and therapeutics. 

“Innovation and intellectual property go hand-in-hand. We look forward to advocating for American ingenuity and the global innovation ecosystem that ushers in new generations of treatments. We will continue to work with this Administration to find solutions that encourage innovation within the life sciences fields and increase patient access to critical diagnostics, therapeutics, and vaccines.” 

Read the full USITC report here.  

Discover More
Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific and investment trends in vaccine development…
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
The Biotechnology Innovation Organization appreciates that USDA and the Biden Administration are aiming to increase access to modern, innovative seeds. We are reviewing USDA’s report, “More and Better Choices for Farmers: Promoting Fair Competition…